Indian regulators ordered Sun Pharmaceutical Industries to stop manufacturing, selling and distributing ophthalmic products from its Assam facility on August 20. The Central Drugs Standard Control Organisation (CDSCO) and the Drugs Controller Assam issued the order after a joint federal-state inspection found failures in the quality management system—the system meant to ensure product quality and safety.
This wasn't the first sign of trouble. In July, Sun Pharma voluntarily recalled about 11 eye-care brands. On August 10, regulators issued a show-cause notice citing those quality management failures. Dissatisfied with the company's response, they escalated to a complete halt of ophthalmic production at the site. The facility cannot resume until it submits a satisfactory compliance report, which is now under review.
The regulator sought more information on the recall of 332 batches of ophthalmic suspension products—liquids used to treat eye conditions. Industry experts, speaking anonymously, told Reuters the affected batches could translate into hundreds of thousands of bottles.
The July recall didn't come out of nowhere. On June 19, the All India Ophthalmological Society (AIOS), a body of nearly 27,000 eye specialists, issued a patient-safety advisory. It told members that multiple institutions had found contamination consistent with pseudomonas species in some batches of Predmet eye drops. The society's adverse events committee noted similar microbiological characteristics across several samples, raising concern about a potential common-source contamination.
Sun Pharma later withdrew Predmet and ordered a wider recall on July 17, covering 11 other eye-care products including Depopred, Brinolar, Brizotim, Lotepred and Nepalact. In an internal notice to stockists, the company called it a "precautionary measure". It did not publicly disclose the affected manufacturing site or what caused the withdrawal.
Reuters reports it remains unclear whether all recalled products were contaminated. One ophthalmic surgeon told the Economic Times he had not found endophthalmitis cases from this product. Yet an AIOS official told Reuters that sealed bottles were investigated and found contaminated, and that infections were reported in Predmet users.
Sun Pharma did not respond to Reuters' requests for comment on the Assam plant and the recall. The company says on its website it follows a single global quality standard.
Ophthalmology contributes about 3% of Sun Pharma's domestic revenue, according to its 2025-26 annual report. Neither the company nor regulators have quantified the loss from the halt. India formulations sales were INR 54,749 million in Q1 FY27, or 36.1% of consolidated sales. Three percent of that is roughly INR 1,640 million a quarter, or about 1% of consolidated sales. That's a ceiling, not an estimate—the Assam site is not necessarily the sole source of ophthalmic products. Transcript
Reuters found that most recalled products were manufactured at the Assam facility in Kokjhar village. Sun has said about 26 eye-care products, including Cequa, Careprost LS, Gatilox DM, Timolet OD and Cafta, are made at other sites. The affected brands are a subset.
The US exposure is less clear. Reuters describes ophthalmology as a key growth area for the US. It is unclear whether any Assam-made eye products were exported, or whether any patients reported adverse effects. Q1 FY27 US sales were US$427 million, down 9.7%, mainly from lenalidomide generic erosion. The halt order itself is an Indian regulatory action. Transcript
Then there's the Organon deal. On October 30, Sun Pharma reported Q2 FY27 consolidated net profit of INR 19.89 billion, down from INR 31.18 billion a year earlier. The drop was dragged by a one-time charge of INR 12.69 billion, largely acquisition-related costs for the planned purchase of Organon, along with provisions linked to India's new labour code framework. The reports attribute the profit decline to this charge, not the Assam matter. Management has said further charges will follow, mostly back-ended and substantially accrued at closing. Transcript +1
The Assam shutdown hits a strategic ambition.
Dilip Shanghvi, Managing Director, said the plant was expected to become "one of the largest facilities in our network to manufacture sterile products". The site is designed to meet global cGMP requirements and can produce tablets, capsules, injectables and eye care products.
Reuters notes that the site was expected to become one of Sun's largest manufacturing hubs for sterile products in a business identified as a key global growth driver. The halt covers only ophthalmic products, not the entire site. But a facility flagged for quality management system failures will likely face closer scrutiny from export-market regulators. That's a risk, not a reported event.
Competitive implications are harder to pin down. India's ophthalmic market is worth about INR 4,721 crore, growing 6% annually. Competitors include Allergan, Micro, Ajanta, Entod, Intas and Alembic. Supply gaps and reputational damage among prescribing eye doctors could let rivals take share. That's plausible but not evidenced.
Sun does have other sterile capacity. The company is building a new sterile-only facility in Madhya Pradesh, which management described on the Q4 FY26 call as aimed at supplying major global geographies. That should reduce dependence on Assam. Transcript +1
This isn't Sun Pharma's first brush with regulators over sterile manufacturing. The US Food and Drug Administration (FDA) classified the Halol plant as Official Action Indicated in August 2022, placed it on Import Alert 66-40 in December 2022, and issued a warning letter that year, amended in October 2023. Management acknowledged in 2023 that earlier remediation "was not adequate" and said it had restructured its quality focus. As of the Q1 FY26 call, Halol was still under a warning letter, with no resolution timeline. Annual Report +5
Mohali and Dadra have also faced FDA actions. Mohali was classified OAI in August 2022 and received a non-compliance letter in April 2023. Dadra was classified OAI after a December 2023 inspection, followed by an FDA warning letter in June 2024. Annual Report +1
Sun's disclosures show zero warning letters in FY2026, against one in FY2025. The Assam case differs—it's an Indian regulator action, not an FDA one, and it's tied to a contamination alert from doctors. But the pattern matters for credibility. Sun says it follows a single global quality standard. Another quality management finding makes that harder to defend. Other
The Assam action didn't happen in a vacuum. CDSCO has been conducting joint inspections with state drug control administrations using a risk-based approach. A committee of two Joint Drugs Controllers at CDSCO headquarters monitors inspections, reporting and follow-up action. Since December 2022, 905 units have been inspected, leading to 694 actions including stop-production orders, licence suspensions or cancellations, warning letters and show-cause notices.
The risk-based guidance rates sites on the risk they pose to patients and product quality, weighing inspection history and past findings. Pairing central and state officers gives the order more authority. The graded toolkit matches what happened here: show-cause notice, then stop-production, with the halt lifted only after a satisfactory report.
Yet one piece is missing: a public health alert. Reuters says the agency did not issue one after the recall. CDSCO does publish monthly Not of Standard Quality drug alerts, but those come from sampling and testing. A company-initiated recall is a different route. The lack of transparency has drawn criticism. An industry expert told the Economic Times that if there is credible evidence of facility contamination, the response should be "clear, transparent and decisive".
Sun Pharma has submitted a compliance report, which regulators are reviewing. The halt stays until a satisfactory report is accepted. The company's Q2 FY27 earnings call recording is on its website, but management comments on the Assam matter are not in the indexed filings. Transcript
The commercial impact so far appears limited. Ophthalmology is 3% of India sales, and the US specialty growth drivers named on recent calls—ILUMYA, ODOMZO and CEQUA—are among the products Sun says are unaffected. But the reputational cost could linger, especially among eye specialists who received the AIOS advisory. Transcript +1
The bigger question is whether this episode affects the planned Organon acquisition, which is expected to close in early 2027 subject to approvals. It also raises the bar for FDA reinspections of Halol and Mohali. Other +1
For now, the story is incomplete. The specific quality lapses, the root cause of the contamination, and the full financial impact remain undisclosed. What's clear is that India's largest drugmaker is under the microscope, and regulators are showing they will act when quality systems fall short.
